+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biological Safety Testing Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • February 2024
  • Region: Global
  • Expert Market Research
  • ID: 5941092

Global Biological Safety Testing Market Outlook

The global biological safety testing market size was valued at USD 4.53 billion in 2023, driven by innovation of testing technologies across the globe. The market size is anticipated to grow at a CAGR of 13.2% during the forecast period of 2024-2032 to achieve a value of USD 20.03 billion by 2032.

Biological Safety Testing: Introduction

Biological safety testing is a crucial process in the biopharmaceutical industry, ensuring that products such as vaccines, therapeutics, and medical devices are free from harmful contaminants like bacteria, viruses, and toxins. This testing involves a series of rigorous procedures, including sterility tests, endotoxin analyses, and mycoplasma detection, aimed at verifying product safety and compliance with regulatory standards. It's essential for protecting patient health and maintaining the integrity and quality of biomedical products.

Key Trends in the Global Biological Safety Testing Market

There's a growing emphasis on regulatory compliance across the globe, leading to more stringent safety testing requirements for biopharmaceutical products. This trend is driving the demand for biological safety testing services.

Innovations in testing technologies, such as rapid microbiological methods (RMM) and high-throughput screening, are enhancing the efficiency and accuracy of biological safety testing.

The increasing production of biologics, including vaccines, monoclonal antibodies, and cell and gene therapies, is driving the need for comprehensive safety testing to ensure product quality and patient safety.

Many biopharmaceutical companies are outsourcing safety testing to specialized laboratories to reduce costs and leverage technical expertise, leading to the growth of the contract testing market.

Events like the COVID-19 pandemic have highlighted the importance of ensuring biological safety, leading to increased investment in safety testing for vaccines and therapeutics.

Global Biological Safety Testing Market Segmentation

Market Breakup by Product Type

  • Reagents and Kits
  • Instruments
  • Other Products

Market Breakup by Test

  • Sterility Tests
  • Bioburden Tests
  • Endotoxin Tests
  • Other Tests

Market Breakup by Application

  • Vaccines and Therapeutics
  • Cellular and Gene Therapy
  • Blood and Blood-Based Therapy
  • Other Applications

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Biological Safety Testing Market Overview

North America is likely to dominate the market due to stringent regulatory standards, a well-established biopharmaceutical industry, and significant investment in research and development. The United States, in particular, is a hub for innovation in biological safety testing technologies.

Europe shows strong growth, driven by robust healthcare systems, comprehensive regulatory frameworks, and a focus on maintaining high safety standards for pharmaceuticals and medical devices. Countries like Germany, the UK, and France are key contributors.

Asia-Pacific experiences rapid growth due to increasing investment in healthcare, rising demand for biopharmaceutical products, and improving regulatory landscapes. Countries like China, Japan, and India are investing heavily in healthcare infrastructure and research, contributing to market growth.

Latin America is an emerging market with growing potential, driven by improvements in healthcare infrastructure, rising investment in the biopharmaceutical sector, and increasing awareness about product safety and quality.

Middle East & Africa shows gradual growth, influenced by increasing investment in healthcare infrastructure, efforts to standardize regulatory frameworks, and a rising focus on healthcare quality and safety.

Global Biological Safety Testing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The Avance Biosciences
  • Avance Biosciences
  • Cytovance Biologics
  • Eurofins Scientific
  • Lonza
  • Merck KGaA
  • Promega Corporation
  • Thermo Fisher Scientific
  • Toxikon
  • WuXi AppTec
  • Biomerieux SA
  • Nelson Laboratories, LLC
  • Almac Group
  • GenScript
  • InvivoGen
  • Maravai LifeSciences


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biological Safety Testing Market Overview
3.1 Global Biological Safety Testing Market Historical Value (2017-2023)
3.2 Global Biological Safety Testing Market Forecast Value (2024-2032)
4 Global Biological Safety Testing Market Landscape
4.1 Global Biological Safety Testing Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biological Safety Testing Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Application
5 Global Biological Safety Testing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biological Safety Testing Market Segmentation
6.1 Global Biological Safety Testing Market by Product Type
6.1.1 Market Overview
6.1.2 Reagents and Kits
6.1.3 Instruments
6.1.4 Other Products
6.2 Global Biological Safety Testing Market by Test
6.2.1 Market Overview
6.2.2 Sterility Tests
6.2.3 Bioburden Tests
6.2.4 Endotoxin Tests
6.2.5 Other Tests
6.3 Global Biological Safety Testing Market by Application
6.3.1 Market Overview
6.3.2 Vaccines and Therapeutics
6.3.3 Cellular and Gene Therapy
6.3.4 Blood and Blood-Based Therapy
6.3.5 Other Applications
6.4 Global Biological Safety Testing Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Biological Safety Testing Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Biological Safety Testing Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Biological Safety Testing Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Biological Safety Testing Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Biological Safety Testing Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Avance Biosciences
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Cytovance Biologics
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Eurofins Scientific
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Lonza
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Merck KGaA
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Promega Corporation
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Thermo Fisher Scientific
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Toxikon
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 WuXi AppTec
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Biomerieux SA
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Nelson Laboratories, LLC
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Almac Group
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 GenScript
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 InvivoGen
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 Maravai LifeSciences
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Biological Safety Testing Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Avance Biosciences
  • Cytovance Biologics
  • Eurofins Scientific
  • Lonza
  • Merck KGaA
  • Promega Corporation
  • Thermo Fisher Scientific
  • Toxikon
  • WuXi AppTec
  • Biomerieux SA
  • Nelson Laboratories LLC
  • Almac Group
  • GenScript
  • InvivoGen
  • Maravai LifeSciences

Methodology

Loading
LOADING...

Table Information